Hims & Hers narrows 2026 revenue forecast as margins contract

What happened

Hims & Hers Health narrowed its 2026 revenue forecast to $3.13 billion to $3.15 billion, below analysts’ $3.21 billion estimate. Its previous forecast was $3.1 billion to $3.3 billion. The company said gross margins, or revenue remaining after direct costs, contracted amid expansion into branded weight-loss drugs and international markets.

Confirmed

Global impact / market context

The lower forecast points to slower expected sales growth than analysts anticipated, while contracting gross margins suggest direct costs are taking a larger share of revenue. If that continues, the company may have less cash available to fund expansion or produce profit from each sale.

Analyst inference

The revised range is narrower and its upper end remains below the analyst estimate stated in the article. Expansion into branded weight-loss drugs and international markets is happening alongside weaker gross margins, so investors may weigh potential sales growth against the cost of serving those markets.

Analyst inference

What to watch

1. Future revenue updates could show whether sales remain within the new $3.13 billion to $3.15 billion forecast or move closer to analysts’ earlier expectations. Analyst inference
2. Further reporting on gross margins could clarify whether expansion into branded weight-loss drugs and international markets continues to raise direct costs relative to revenue. Analyst inference
3. The next financial results may indicate whether the company can grow sales in new markets while preserving enough revenue after direct costs to support its business. Analyst inference

Evidence

• Original source link unavailable